Estrella Immunopharma (ESLA) Payables (2021 - 2026)

Estrella Immunopharma (ESLA) has reported Payables for 6 consecutive years, with $695456.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables rose 254.65% year-over-year to $695456.0 in Q2 2026; TTM through Jun 2026 was $695456.0, a 254.65% increase from a year earlier, with the FY2025 full-year figure at $911286.0, up 20447.6% from the prior year.
• Payables was $695456.0 for Q2 2026 at Estrella Immunopharma, up from $480079.0 in the prior quarter.
• Over five years, Payables peaked at $9.6 million in Q3 2023 and troughed at $4435.0 in Q4 2024.
• A 5-year average of $926948.5 and a median of $385076.0 in 2022 frame the typical range for Payables.
• Across the five-year window, Payables jumped 23403.2% in 2022 and plunged 99.95% in 2024, its largest moves.
• Over 5 years, Payables stood at $379166.0 in 2022, then slumped by 79.67% to $77076.0 in 2023, then sank by 94.25% to $4435.0 in 2024, then surged by 20447.6% to $911286.0 in 2025, then fell by 23.68% to $695456.0 in 2026.
• The last three Payables figures came in at $695456.0 (Q2 2026), $480079.0 (Q1 2026), and $911286.0 (Q4 2025), per Business Quant data.